Last reviewed · How we verify
Amoxicilli
At a glance
| Generic name | Amoxicilli |
|---|---|
| Sponsor | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. |
| Target | 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Acute bacterial sinusitis
- Acute exacerbation of chronic bronchitis
- Acute otitis media
- Bacterial pneumonia
- Bacterial urinary infection
- Duodenal Ulcer due to H. Pylori
- E. Coli Genitourinary Tract Infection
- Enterococcus Genitourinary Tract Infection
- Escherichia coli urinary tract infection
- Genitourinary Tract Infection due to Proteus
- Genitourinary Tract Infections
- Haemophilus Influenzae Acute Otitis Media
- Haemophilus Influenzae Chronic Bronchitis
- Haemophilus Influenzae Pharyngitis
- Haemophilus Parainfluenzae Pneumonia
- Haemophilus influenzae pneumonia
- Infection caused by Helicobacter pylori
- Infection due to Escherichia coli
- Infection due to Staphylococcus aureus
- Infection of skin AND/OR subcutaneous tissue
Common side effects
- Diarrhea/loose stools
- Nausea
- Skin rashes and urticaria
- Vomiting
- Vaginitis
- Abdominal discomfort
- Flatulence
- Headache
Serious adverse events
- Anaphylactic/anaphylactoid reactions (including shock)
- Pseudomembranous colitis
- Stevens-Johnson Syndrome (SJS)
- Toxic Epidermal Necrolysis (TEN)
- Angioedema
- Hepatic dysfunction/hepatitis
- Serum sickness-like reactions
- Drug-induced enterocolitis syndrome (DIES)
- Hypersensitivity vasculitis
- DRESS syndrome
Key clinical trials
- Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori (PHASE4)
- Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |